Donor T Cells Expressing Active STAT6 for GVHD Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hematopoietic cell transplantation methods, such as bone marrow transplantation, often result in graft-versus-host disease (GVHD), a severe complication that can be lethal and is difficult to manage, while also requiring the use of toxic immune suppressive medications to regulate GVHD and preserve the graft-versus-tumor (GVT) effect.
Innovation Solution
Engineering donor T cells to express a continuously active form of STAT6, which promotes a Th2 immune response, thereby regulating GVHD and preserving the GVT effect without causing severe GVHD, and using these genetically modified T cells in conjunction with hematopoietic stem cell transplants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If donor T cells are transferred with stem cells to restore immune function and fight cancer, then the graft-versus-tumor effect is improved, but graft-versus-host disease occurs
Solution Approach 1:
The patent applies local quality by selectively modifying the functional properties of donor T cells through STAT6 activation. The modified T cells acquire enhanced regulatory capabilities (local functional change) while maintaining their anti-tumor activity, allowing them to differentiate between harmful host-directed responses and beneficial tumor-directed responses.
Solution Approach 2:
The patent changes the activation state parameter of STAT6 in donor T cells from basal to constitutively active. This parameter change fundamentally alters the T cells' functional profile, inducing a regulatory phenotype that suppresses GVHD while preserving GVT activity through shifted cytokine production and reduced inflammatory responses.
2Object-affected harmful factors
If high dose steroids are used to treat GVHD, then GVHD is suppressed, but toxic side effects increase
Solution Approach 1:
The patent applies preliminary action by pre-modifying donor T cells with activated STAT6 before transplantation. This preemptive genetic modification programs the T cells to inherently resist causing GVHD, eliminating the need for post-transplant steroid intervention and avoiding all associated toxicities while still achieving GVHD control.
Solution Approach 2:
The patent converts the potentially harmful alloreactive potential of donor T cells into a beneficial regulatory function. By activating STAT6, the T cells' aggressive immune response is redirected toward a regulatory phenotype that protects against GVHD while maintaining anti-tumor activity, transforming a harmful characteristic into a therapeutic advantage.
3Reliability
If the immune system is wiped out before transplant to prepare for stem cell engraftment, then transplant success is improved, but infection risk increases
Solution Approach 1:
The patent applies preliminary action by pre-activating STAT6 in donor T cells before transplantation. This advance preparation ensures that the transferred T cells immediately possess enhanced regulatory and protective functions, enabling them to更快 establish immune control and protect against infections during the vulnerable post-transplant period.
Solution Approach 2:
The patent implements feedback mechanisms through constitutively active STAT6, which continuously monitors and regulates immune responses. This ongoing feedback control allows the modified T cells to dynamically adjust their activity to protect against infections while preventing excessive responses that could cause GVHD, maintaining immune balance during recovery.
Data Source
AI summary
Provided herein is the use of donor T cells that express a continuously active form of STAT6, e.g., before or during BMT/HCT or after BMT/HCT, the use of autologous T cells genetically engineered to express a continuously active form of STAT6 to prevent, inhibit or treat immune diseases including autoimmune diseases and the use of T cells genetically engineered to express a continuously active form of STAT6 to enhance an immune response to a vaccine.